Nicolino Ruperto MD, MPH*, Hermine I Brunner MD, MSc, MBA*, Olga Synoverska MD, Tracy V Ting MD, MSc, RhMSUS, Carlos Abud Mendoza MD, Alberto Spindler MD, Yulia Vyzhga MD, Katherine Marzan MD, Lyudmila Grebenkina MD, Irit Tirosh MD, Lisa Imundo MD, Rita Jerath MD, Daniel J Kingsbury MD, Betul Sozeri MD, Sheetal S Vora MD, Sampath Prahalad MD, Elena Zholobova MD, Yonatan Butbul Aviel MD, Vyacheslav Chasnyk MD, Melissa Lerman MD, Kabita Nanda MD, Heinrike Schmeling MD, Heather Tory MD, Yosef Uziel MD, Diego Oscar Viola MD, Holly B Posner MD, Keith S Kanik MD, Ann Wouters MSc, Cheng Chang PhD, Richard Zhang PhD, Irina Lazariciu MSc, Ming-Ann Hsu MPH, Ricardo M Suehiro MD, Alberto Martini MD*, and Daniel J Lovell MD, MPH*, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trialLancet 2021, November 9
Year:
2021 -